PolynovoCALZF 74 PE Ratio without NRI is 51.67 as of Jun. 29, 2026, which is 51% below its 10-year median of 106.32. GuruFocus rates CALZF with a GF Score™ of 74/100 and a GF Value™ of $2.21 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 446 Medical Devices & Instruments companies, Polynovo ranks worse than 81.84% on this metric.
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-06-29), Polynovo's share price is $0.62.
Polynovo's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was $0.01. Therefore, Polynovo's PE Ratio without NRI for today is 51.67.
During the past 13 years, Polynovo's highest PE Ratio without NRI was 330.00. The lowest was 47.11. And the median was 106.32.
Polynovo's EPS without NRI for the
six
months ended in Dec. 2025 was $0.00.
Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was $0.01.
Polynovo Ltd stock PE Ratio (=47.89) is close to 2-year low of 47.11.
During the past years, Polynovo's highestPE Ratio (TTM) was 330.00. The lowest was 47.11. And the median was 106.32.
Polynovo's
EPS (Diluted) for the
six
months ended in Dec. 2025 was $0.00.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.01.
Polynovo's EPS (Basic) for the
six
months ended in Dec. 2025 was $0.00.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.01.
Polynovo (OTCPK:CALZF) PE Ratio without NRI Explanation
The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.
If a company loses money, the PE Ratio becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.
Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.
Polynovo PE Ratio without NRI Related Terms
Polynovo PE Ratio without NRI Historical Data
* Premium members only.
The historical data trend for Polynovo's PE Ratio without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CALZF vs ABT, SYK, MDT: PE Ratio without NRI Comparison
For the Medical Devices subindustry, Polynovo's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Polynovo PE Ratio without NRI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Polynovo's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Polynovo's PE Ratio without NRI falls into.
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.
Polynovo's PE Ratio without NRI for today is calculated as
Polynovo's Share Price of today is $0.62.
For company reported semi-annually, Polynovo's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.
For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Polynovo (CALZF) has a PE Ratio without NRI of 51.67 as of Jun. 29, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Polynovo and its competitors. This is 51% below median its historical median of 106.32. Over the past decade, Polynovo's PE Ratio without NRI has ranged from 47.11 to 330.00. According to the industry distribution chart, Polynovo ranks #365 out of 446 companies in the Medical Devices & Instruments industry, placing it in the top 81.8%.
Is Polynovo's PE Ratio without NRI too high?
Polynovo's current PE Ratio without NRI of 51.67 is 51% below median its 10-year median of 106.32. Over the past 10 years, this metric has ranged from a low of 47.11 to a high of 330.00. The Medical Devices & Instruments industry median PE Ratio without NRI is 23.18. Polynovo's value of 51.67 is 123% above this industry median. Based on the distribution chart, Polynovo ranks #365 out of 446 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Polynovo has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Polynovo's PE Ratio without NRI compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Polynovo ranks #365 out of 446 companies for PE Ratio without NRI. This places Polynovo in the lower half of its industry. The industry median PE Ratio without NRI is 23.18. Polynovo's value of 51.67 is 123% above this benchmark. Historically, Polynovo's own PE Ratio without NRI has ranged from 47.11 to 330.00 over the past decade. While the company's 10-year median is 106.32 vs. the industry median of 23.18, Polynovo has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Medical Devices & Instruments company?
The median PE Ratio without NRI among Medical Devices & Instruments companies is 23.18, based on 446 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Polynovo's current PE Ratio without NRI of 51.67 is 123% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Polynovo and its competitors. For the Medical Devices & Instruments industry, the median PE Ratio without NRI is 23.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Polynovo's current PE Ratio without NRI is 51.67, which is 51% below median its own 10-year median of 106.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polynovo stock overvalued right now?
Based on GuruFocus' analysis, Polynovo (CALZF) is currently considered Significantly Undervalued. The stock's GF Value™ is $2.21, compared to a current price of $0.62 — trading 71.9% below its estimated fair value. The current PE Ratio without NRI is 51.67, which is 51% below median its 10-year median of 106.32 and 123% above the Medical Devices & Instruments industry median of 23.18. Polynovo's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For Polynovo (CALZF), the current PE Ratio without NRI is 51.67 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Polynovo (CALZF) Overvalued in 2026?
Based on GuruFocus' analysis, Polynovo stock appears to be undervalued.
The current stock price of $0.62 is trading 71.9% below its estimated GF Value™ of $2.21.
GuruFocus considers Polynovo to be Significantly Undervalued.
Key valuation signals for CALZF:
PE Ratio without NRI: 51.67 (51% below median its 10-year median of 106.32)
GF Value™: $2.21 vs. price of $0.62 (71.9% below fair value)
Industry Position: 123% above the Medical Devices & Instruments median (#365 of 446)
No single metric tells the full story. See the CALZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita's RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.
74GF Score
Get the complete analysis for CALZF
PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CALZF has been successfully added to your 
